Blood test for tumor DNA in Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at whether a blood test that checks for tiny pieces of tumor DNA (called ctDNA) can help predict how Hodgkin lymphoma will progress. It is for adults who have just been diagnosed with classical Hodgkin lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You must have been newly diagnosed with a type of Hodgkin lymphoma called classical Hodgkin lymphoma (cHL)
- You must be willing to sign a consent form to be in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test to detect cancer DNA (ctDNA) in children and young adults with classical Hodgkin lymphoma. The goal is to see if this non-invasive test can help track how well treatment is working.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
This trial studies whether a blood test (ctDNA) can help doctors safely reduce chemotherapy for people with advanced Hodgkin lymphoma. If you have stage 3 or 4 Hodgkin lymphoma that hasn't been treated yet and are healthy enough for strong chemo, this study may be an option for you.
This study checks a blood test that looks for small DNA fragments (“cell-free DNA”) to find cancer changes that could guide treatment in diffuse large B-cell lymphoma. It also looks for “minimal residual disease,” meaning tiny amounts of lymphoma that may remain after treatment, and whether this test works across community cancer centers in Texas.
This study tests whether a new blood test can detect multiple types of cancer early by analyzing DNA fragments in your blood. Researchers are enrolling people recently diagnosed with cancer (before treatment starts) and people without cancer to develop and validate this detection method.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
Hear when a new Prognostic Cancer Model trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.